Home/Filings/4/0001641172-25-026397
4//SEC Filing

Yu Yong 4

Accession 0001641172-25-026397

CIK 0001231457other

Filed

Sep 2, 8:00 PM ET

Accepted

Sep 3, 4:15 PM ET

Size

12.4 KB

Accession

0001641172-25-026397

Insider Transaction Report

Form 4
Period: 2025-09-01
Yu Yong
VP, Clinical Trial Operations
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-09-01207,6520 total
    Exercise: $6.00Exp: 2029-09-20Common stock (207,652 underlying)
  • Award

    Stock Option (Right to Buy)

    2025-09-01+207,652207,652 total
    Exercise: $3.33Exp: 2029-09-20Common stock (207,652 underlying)
  • Award

    Stock Option (Right to Buy)

    2025-09-01+65,00065,000 total
    Exercise: $3.33Exp: 2033-09-10Common stock (65,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-09-0165,0000 total
    Exercise: $22.40Exp: 2033-09-10Common stock (65,000 underlying)
Footnotes (3)
  • [F1]The shares subject to the option are fully vested.
  • [F2]The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options.
  • [F3]The shares subject to the option vest as follows: 25% on September 11, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.

Documents

1 file

Issuer

GENELUX Corp

CIK 0001231457

Entity typeother

Related Parties

1
  • filerCIK 0001937482

Filing Metadata

Form type
4
Filed
Sep 2, 8:00 PM ET
Accepted
Sep 3, 4:15 PM ET
Size
12.4 KB